EGFR and neoplasm: The introduction of liquid biopsies (LB) for the detection of Epidermal growth factor receptor (EGFR) mutations at diagnosis as well as at tumor progression during treatment to identify resistance to tyrosine kinase inhibitors (TKIs) treatment has revolutionized care of non-small-cell lung cancer (NSCLC) patients (Oellerich et al., 2019).